<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title>PLoS ONE</journal-title><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">09-PONE-RA-09234R1</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0005988</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Molecular Biology/Post-Translational Regulation of Gene Expression</subject><subject>Dermatology/Psoriasis and Other Inflammatory Diseases</subject><subject>Pathology/Immunology</subject></subj-group></article-categories><title-group><article-title>20-Hydroxycholecalciferol, Product of Vitamin D3 Hydroxylation by P450scc, Decreases NF-&#x003ba;B Activity by Increasing I&#x003ba;B&#x003b1; Levels in Human Keratinocytes</article-title><alt-title alt-title-type="running-head">20OHD3 Decreases NF-&#x003ba;B</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Janjetovic</surname><given-names>Zorica</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zmijewski</surname><given-names>Michal A.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tuckey</surname><given-names>Robert C.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>DeLeon</surname><given-names>Damon A.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Nguyen</surname><given-names>Minh N.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pfeffer</surname><given-names>Lawrence M.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Slominski</surname><given-names>Andrzej T.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Department of Pathology and Laboratory Medicine, the Center for Cancer Research, University of Tennessee Health Science Center, Memphis, Tennessee, United States of America</addr-line></aff><aff id="aff2"><label>2</label><addr-line>School of Biomedical, Biomolecular and Chemical Sciences, University of Western Australia, Crawley, Australia</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Schauber</surname><given-names>J&#x000fc;rgen</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">Ludwig-Maximilians-University, Germany</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>aslominski@utmem.edu</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: ZJ LMP ATS. Performed the experiments: ZJ MAZ RCT DAD MNN. Analyzed the data: ZJ MAZ RCT LMP ATS. Contributed reagents/materials/analysis tools: ZJ RCT. Wrote the paper: ZJ RCT LMP ATS.</p></fn></author-notes><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>19</day><month>6</month><year>2009</year></pub-date><volume>4</volume><issue>6</issue><elocation-id>e5988</elocation-id><history><date date-type="received"><day>16</day><month>3</month><year>2009</year></date><date date-type="accepted"><day>5</day><month>5</month><year>2009</year></date></history><copyright-statement>Janjetovic et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement><copyright-year>2009</copyright-year><abstract><p>The side chain of vitamin D3 is hydroxylated in a sequential manner by cytochrome P450scc (CYP11A1) to form 20-hydroxycholecalciferol, which can induce growth arrest and differentiation of both primary and immortalized epidermal keratinocytes. Since nuclear factor-&#x003ba;B (NF-&#x003ba;B) plays a pivotal role in the regulation of cell proliferation, differentiation and apoptosis, we examined the capability of 20-hydroxycholecalciferol to modulate the activity of NF-&#x003ba;B, using 1,25-dihydroxycholecalciferol (calcitriol) as a positive control. 20-hydroxycholecalciferol inhibits the activation of NF&#x003ba;B DNA binding activity as well as NF-&#x003ba;B-driven reporter gene activity in keratinocytes. Also, 20-hydroxycholecalciferol induced significant increases in the mRNA and protein levels of the NF-&#x003ba;B inhibitor protein, I&#x003ba;B&#x003b1;, in a time dependent manner, while no changes in total NF-&#x003ba;B-p65 mRNA or protein levels were observed. Another measure of NF-&#x003ba;B activity, p65 translocation from the cytoplasm into the nucleus was also inhibited in extracts of 20-hydroxycholecalciferol treated keratinocytes. Increased I&#x003ba;B&#x003b1; was concomitantly observed in cytosolic extracts of 20-hydroxycholecalciferol treated keratinocytes, as determined by immunoblotting and immunofluorescent staining. In keratinocytes lacking vitamin D receptor (VDR), 20-hydroxycholecalciferol did not affect I&#x003ba;B&#x003b1; mRNA levels, indicating that it requires VDR for its action on NF-&#x003ba;B activity. Comparison of the effects of calcitrol, hormonally active form of vitamin D3, with 20-hydrocholecalciferol show that both agents have a similar potency in inhibiting NF-&#x003ba;B. Since NF-&#x003ba;B is a major transcription factor for the induction of inflammatory mediators, our findings indicate that 20-hydroxycholecalciferol may be an effective therapeutic agent for inflammatory and hyperproliferative skin diseases.</p></abstract><counts><page-count count="12"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Human keratinocytes have the ability to metabolize vitamin D3 autonomously <xref ref-type="bibr" rid="pone.0005988-Lehmann1">&#x0005b;1&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-Holick1">&#x0005b;2&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-Bikle1">&#x0005b;3&#x0005d;</xref>. Not only are they the site of conversion of 7-dehydrocholesterol (7DHC) to vitamin D3 following UVB-radiation <xref ref-type="bibr" rid="pone.0005988-Holick1">&#x0005b;2&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-Webb1">&#x0005b;4&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-Holick2">&#x0005b;5&#x0005d;</xref>, but they also express enzymes to hydroxylate vitamin D3 to the hormonally active form known as calcitriol or 1,25-dihydroxyvitamin D3 (1,25(OH)<sub>2</sub>D3). Thus, keratinocytes are the site of production and the target for vitamin D3 <xref ref-type="bibr" rid="pone.0005988-Bikle1">&#x0005b;3&#x0005d;</xref>. We have recently identified new pathway for metabolism of vitamin D and pro-vitamin D that is catalyzed by cytochrome P450scc (CYP11A1) <xref ref-type="bibr" rid="pone.0005988-Slominski1">&#x0005b;6&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-Slominski2">&#x0005b;7&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-Slominski3">&#x0005b;8&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-Tuckey1">&#x0005b;9&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-Tuckey2">&#x0005b;10&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-Tuckey3">&#x0005b;11&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-Slominski4">&#x0005b;12&#x0005d;</xref>, the enzyme catalyzing the conversion of cholesterol to pregnenolone for steroid hormone synthesis <xref ref-type="bibr" rid="pone.0005988-Tuckey4">&#x0005b;13&#x0005d;</xref>. 20-Hydroxyvitamin D3 (20(OH)D3) is the major product of P450scc activation of vitamin D3 as well as an intermediate in the sequential synthesis of other hydroxylated derivatives including 20,23-dihydroxyvitamin D3 (20,23(OH)2D3 and 17,20,23-trihydroxyvitamin D3 (17,20,23(OH)3D3) (see <xref ref-type="fig" rid="pone-0005988-g001">Figure 1</xref>) <xref ref-type="bibr" rid="pone.0005988-Slominski2">&#x0005b;7&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-Tuckey2">&#x0005b;10&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-Tuckey3">&#x0005b;11&#x0005d;</xref>. We postulated that 20(OH)D3 could have systemic effects when produced in organs expressing high levels of P450scc, such as adrenal cortex, corpus luteum, follicles and placenta <xref ref-type="bibr" rid="pone.0005988-Slominski2">&#x0005b;7&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-Lehmann2">&#x0005b;14&#x0005d;</xref>, while in organs expressing low levels of P450scc, such as skin <xref ref-type="bibr" rid="pone.0005988-Slominski3">&#x0005b;8&#x0005d;</xref>, 20(OH)D3 could serve local paracrine, autocrine or intracrine roles. In fact, we have recently demonstrated that 20(OH)D3 can stimulate differentiation and inhibit proliferation of keratinocyte cultured in vitro <xref ref-type="bibr" rid="pone.0005988-Zbytek1">&#x0005b;15&#x0005d;</xref>.</p><fig id="pone-0005988-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005988.g001</object-id><label>Figure 1</label><caption><title>P450scc (CYP11A1) can hydroxylate vitamin D3 to 20-hydroxycholecalciferol with following sequential metabolism to other hydroxyderivatives <xref ref-type="bibr" rid="pone.0005988-Tuckey2">&#x0005b;10&#x0005d;</xref>.</title></caption><graphic xlink:href="pone.0005988.g001"/></fig><p>Vitamin D3 has a wide variety of actions in autoimmune diseases and cancer <xref ref-type="bibr" rid="pone.0005988-Deeb1">&#x0005b;16&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-Bikle2">&#x0005b;17&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-Bouillon1">&#x0005b;18&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-vandenBemd1">&#x0005b;19&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-Spina1">&#x0005b;20&#x0005d;</xref> as well as on bone physiology and blood pressure <xref ref-type="bibr" rid="pone.0005988-Holick3">&#x0005b;21&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-Dusso1">&#x0005b;22&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-Nagpal1">&#x0005b;23&#x0005d;</xref>. The biological role of its metabolite 20(OH)D3 is only partially known <xref ref-type="bibr" rid="pone.0005988-Zbytek1">&#x0005b;15&#x0005d;</xref>, while it is well documented that 1,25(OH)<sub>2</sub>D3 and its derivatives <xref ref-type="bibr" rid="pone.0005988-Saito1">&#x0005b;24&#x0005d;</xref> have diverse biological activities on multiple cell lineages <xref ref-type="bibr" rid="pone.0005988-Holick1">&#x0005b;2&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-Holick3">&#x0005b;21&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-Holick4">&#x0005b;25&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-Bikle3">&#x0005b;26&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-Wiseman1">&#x0005b;27&#x0005d;</xref>, including modulation of the skin immune system (SIS) and protection of the skin against UVB-induced damage <xref ref-type="bibr" rid="pone.0005988-Holick4">&#x0005b;25&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-Bikle3">&#x0005b;26&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-Holick5">&#x0005b;28&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-Bikle4">&#x0005b;29&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-Bikle5">&#x0005b;30&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-Holick6">&#x0005b;31&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-Bikle6">&#x0005b;32&#x0005d;</xref>.</p><p>Inflammation and proliferation are regulated by a plethora of transcription factors, with nuclear factor-&#x003ba;B (NF-&#x003ba;B) considered to be a master regulator of these processes (reviewed in <xref ref-type="bibr" rid="pone.0005988-Li1">&#x0005b;33&#x0005d;</xref>). NF-&#x003ba;B is also important in the development, prevention and therapy of cancer <xref ref-type="bibr" rid="pone.0005988-VanWaes1">&#x0005b;34&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-Liu1">&#x0005b;35&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-Umezawa1">&#x0005b;36&#x0005d;</xref>. NF-&#x003ba;B activity is stimulated by many pathways that converge on I&#x003ba;B kinases, including the signaling pathways activated by various cytokines, such as the proinflammatory cytokine IL-1 (reviewed in <xref ref-type="bibr" rid="pone.0005988-Grone1">&#x0005b;37&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-Freedberg1">&#x0005b;38&#x0005d;</xref>), lipopolysaccharide (LPS) and tumor necrosis factor &#x003b1; (TNF-&#x003b1;) <xref ref-type="bibr" rid="pone.0005988-Banno1">&#x0005b;39&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-Banno2">&#x0005b;40&#x0005d;</xref>. In mammals, the NF-&#x003ba;B family of proteins includes NF-&#x003ba;B1 (p105 processed to p50), NF-&#x003ba;B2 (p100 processed to p52), RelA (p65), RelB and cRel <xref ref-type="bibr" rid="pone.0005988-Hayden1">&#x0005b;41&#x0005d;</xref>. Phosphorylation and subsequent degradation of I&#x003ba;B proteins allow for translocation of cytoplasmic NF-&#x003ba;B into the nucleus, where NF-&#x003ba;B binds to specific promoter/enhancer elements to regulate the expression of specific genes <xref ref-type="bibr" rid="pone.0005988-Li1">&#x0005b;33&#x0005d;</xref>. NF-&#x003ba;B regulated genes play important roles in inflammation, immunity, cell growth and cell survival <xref ref-type="bibr" rid="pone.0005988-Du1">&#x0005b;42&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-Wei1">&#x0005b;43&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-Yang1">&#x0005b;44&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-Pfeffer1">&#x0005b;45&#x0005d;</xref>.</p><p>NF-&#x003ba;B activation is mediated through the activation of specific I&#x003ba;B kinases (IKKs) and the subsequent phosphorylation of I&#x003ba;B. The pathway leading to proteolysis of I&#x003ba;B is denoted as the canonical NF-&#x003ba;B activation pathway. NF-&#x003ba;B activation also occurs through the &#x02018;noncanonical&#x02019; pathway, which does not involve I&#x003ba;B degradation and is activated by various agents, including interferon-&#x003b1;/&#x003b2;, lipopolysaccharide, the LMP1 protein of Epstein-Barr virus, B-cell activating factor and lymphotoxin-&#x003b2; <xref ref-type="bibr" rid="pone.0005988-Du1">&#x0005b;42&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-Pomerantz1">&#x0005b;46&#x0005d;</xref>.</p><p>Vitamin D and various synthetic vitamin D analogues have been widely used in the treatment of psoriasis <xref ref-type="bibr" rid="pone.0005988-Schon1">&#x0005b;47&#x0005d;</xref> and other inflammatory/hyperproliferative skin disorders <xref ref-type="bibr" rid="pone.0005988-Nagpal2">&#x0005b;48&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-Masuda1">&#x0005b;49&#x0005d;</xref>. The cellular actions of 1,25(OH)<sub>2</sub>D3, the bioactive form of vitamin D, are not fully understood, but its effects have traditionally been ascribed to its binding to the vitamin D receptor (VDR) <xref ref-type="bibr" rid="pone.0005988-Bikle7">&#x0005b;50&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-Oda1">&#x0005b;51&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-Hawker1">&#x0005b;52&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-Zella1">&#x0005b;53&#x0005d;</xref>. NF-&#x003ba;B plays an important role in protecting keratinocytes against apoptosis during programmed cornification <xref ref-type="bibr" rid="pone.0005988-Lippens1">&#x0005b;54&#x0005d;</xref>. In normal human keratinocytes, 1,25(OH)<sub>2</sub>D3 reduces NF-&#x003ba;B DNA binding activity by increasing I&#x003ba;B&#x003b1; protein levels, which inhibits IL-8 production <xref ref-type="bibr" rid="pone.0005988-Riis1">&#x0005b;55&#x0005d;</xref>. A similar effect is also seen in murine macrophages <xref ref-type="bibr" rid="pone.0005988-CohenLahav1">&#x0005b;56&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-CohenLahav2">&#x0005b;57&#x0005d;</xref>. Effects of 1,25(OH)<sub>2</sub>D3 on NF-&#x003ba;B that are not mediated by the VDR have also been reported for fibroblasts lacking the VDR <xref ref-type="bibr" rid="pone.0005988-Sun1">&#x0005b;58&#x0005d;</xref>.</p><p>In the present study we have examined the effects of 20(OH)D3 on NF-&#x003ba;B signaling in comparison to well defined effects of 1,25(OH)<sub>2</sub>D3. Since NF-&#x003ba;B dysregulation induces malignant transformation of HaCaT keratinocytes, but not of normal keratinocytes <xref ref-type="bibr" rid="pone.0005988-Ren1">&#x0005b;59&#x0005d;</xref>, we used in these studies both immortalized human HaCaT keratinocytes and primary epidermal keratinocytes, isolated from human neonatal foreskin (HEKn). The effects of 1,25(OH)<sub>2</sub>D3 on both expression of genes involved in its metabolism and the biological activity of the encoded proteins have previously been studied in these cells <xref ref-type="bibr" rid="pone.0005988-Bikle3">&#x0005b;26&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-Bar1">&#x0005b;60&#x0005d;</xref>. Recent data from our laboratories indicates that 20(OH)D3 can be produced by adrenal mitochondria <xref ref-type="bibr" rid="pone.0005988-Slominski2">&#x0005b;7&#x0005d;</xref>, that adrenal glands ex-vivo can transform 7DHC to 5,7-diene products <xref ref-type="bibr" rid="pone.0005988-Slominski5">&#x0005b;61&#x0005d;</xref> that in the skin can be converted to biologically active vitamin D-like products <xref ref-type="bibr" rid="pone.0005988-Zmijewski1">&#x0005b;62&#x0005d;</xref>. Therefore, action of 20(OH)D3 on NF-&#x003ba;B activity would suggest a role for a novel endogenous secosteroidogenic metabolic pathway <xref ref-type="bibr" rid="pone.0005988-Slominski2">&#x0005b;7&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-Slominski3">&#x0005b;8&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-Tuckey1">&#x0005b;9&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-Tuckey2">&#x0005b;10&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-Tuckey3">&#x0005b;11&#x0005d;</xref> in the regulation of the systemic and cutaneous immune activity.</p></sec><sec id="s2"><title>Results</title><sec id="s2a"><title>20-Hydroxycholecalciferol inhibits NF-&#x003ba;B DNA binding activity in keratinocytes</title><p>In initial experiments we determined that 20(OH)D3 at 100 nM was optimal for inducing biological actions like stimulation of keratinocytes differentiation and inhibition of cell proliferation <xref ref-type="bibr" rid="pone.0005988-Zbytek1">&#x0005b;15&#x0005d;</xref>. Next we examined the effect of 20(OH)D3 on NF-&#x003ba;B activity in keratinocytes by assaying nuclear extracts of 20(OH)D3-stimulated cells by DNA-binding assays. Primary human keratinocytes and HaCaT cells were incubated with 100 nM 20(OH)D3, nuclear extracts were prepared and incubated with an NF-&#x003ba;B oligonucleotide probe based on the &#x003ba;B binding site in the immunoglobulin light chain enhancer. As shown in <xref ref-type="fig" rid="pone-0005988-g002">figure 2A and 2C</xref>, a time dependent decrease in nuclear protein binding to the &#x003ba;B response element was observed in extracts from 20(OH)D3-treated cells. Inhibition of NF-&#x003ba;B activity was observed within 30 minutes of 20(OH)D3 addition. Maximum inhibition was reached by 4 hours, and inhibition persisted up to 24 hours. This effect was no longer observed after 48 hours. Treatment with 1,25(OH)<sub>2</sub>D3 also had similar inhibitory effect of NF-&#x003ba;B activity (data not shown). High basal NF-&#x003ba;B activity in HaCaT cells is probably due to serum deprivation of cells, since previously we have demonstrated that serum deprivation triggers NF-&#x003ba;B activation in HaCaT cells <xref ref-type="bibr" rid="pone.0005988-Zbytek2">&#x0005b;63&#x0005d;</xref>.</p><fig id="pone-0005988-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005988.g002</object-id><label>Figure 2</label><caption><title>20(OH)D3 treatment inhibits the activation of NF&#x003ba;B DNA binding activity in keratinocytes.</title><p>Nuclear extracts were prepared from human keratinocytes, normal and HaCaT, treated with 100 nM 20(OH)D3 for indicated time periods, and were subjected to EMSA (A,C). Nuclear extracts were preincubated with NF-&#x003ba;B antibodies (p65 and p50) and subjected to supershift assay (B,D). &#x0201c;Cold&#x0201d; represents nuclear extract preincubated with an excess of unlabelled oligonucleotide.</p></caption><graphic xlink:href="pone.0005988.g002"/></fig><p>In order to determine the composition of 20(OH)D3-induced NF-&#x003ba;B complexes, nuclear extracts were preincubated with antibodies against the p65 and p50 NF-&#x003ba;B proteins and analyzed by supershift assays. As shown in <xref ref-type="fig" rid="pone-0005988-g002">figure 2B and 2D</xref>, the 20(OH)D3-induced complex contains both p50 and p65 proteins. The specificity of the binding to the &#x003ba;B probe was determined by incubating nuclear extract with excess unlabeled (cold) NF-&#x003ba;B oligonucleotide. Since excess unlabeled NF-&#x003ba;B oligonucleotide competed out DNA binding to the &#x003ba;B probe, NF-&#x003ba;B binding was considered specific.</p></sec><sec id="s2b"><title>20-Hydroxycholecalciferol inhibits NF&#x003ba;B-driven reporter gene activity in keratinocytes</title><p>In order to determine functional consequences of the decreased NF-&#x003ba;B DNA binding activity in the keratinocytes treated with 20(OH)D3, we performed gene reporter assays to determine NF-&#x003ba;B driven transcriptional activity (<xref ref-type="fig" rid="pone-0005988-g003">Fig. 3</xref>). HaCaT and normal human keratinocytes were transiently transfected with the pNF&#x003ba;B-Luc construct, which contained the firefly luciferase reporter gene driven by NF-&#x003ba;B. In the presence of 1,25(OH)<sub>2</sub>D3 or 20(OH)D3, basal luciferase activity decreased (<xref ref-type="fig" rid="pone-0005988-g003">Fig. 3</xref>). The inhibitory effect was more pronounced in normal human keratinocytes, with approximately a 2.5-fold decrease in the reporter activity (p&#x0003c;0.01) (<xref ref-type="fig" rid="pone-0005988-g003">Fig. 3A</xref>). In immortalized keratinocytes (HaCaT) the decrease in activity was less pronounced, but was also statistically significant (p&#x0003c;0.05) (<xref ref-type="fig" rid="pone-0005988-g003">Fig. 3A</xref>). 20(OH)D3 and 1,25(OH)<sub>2</sub>D3 had similar potency in inhibiting the NF-&#x003ba;B driven reporter in keratinocytes. Interestingly, NF-&#x003ba;B activity was significantly inhibited even after 24 hours of treatment with either agent (<xref ref-type="fig" rid="pone-0005988-g003">Fig. 3A</xref>).</p><fig id="pone-0005988-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005988.g003</object-id><label>Figure 3</label><caption><title>20(OH)D3 treatment inhibits the activation of NF&#x003ba;B-dependant activity in keratinocytes.</title><p>Keratinocytes were transiently transfected with a NF&#x003ba;B-Luc construct for 24 h then treated with 100 nM 20(OH)D3, 1,25(OH)<sub>2</sub>D3 or ethanol as a vehicle for the indicated time periods (A), or additionally stimulated with LPS (1 &#x000b5;g/ml) or IL-1&#x003b1; (10 ng/ml) for 30 min (B and C, respectively). Cell lysates prepared from HaCaT and normal human keratinocytes were assayed for luciferase activity. The data from six experiments performed in quadruplicate are presented as means&#x000b1;STDEV. &#x0002a;p&#x0003c;0.05 and &#x0002a;&#x0002a;p&#x0003c;0.01 between control (non treated cells) and treated cells.</p></caption><graphic xlink:href="pone.0005988.g003"/></fig><p>To further characterize the inhibitory activity of 20(OH)D3 and 1,25(OH)<sub>2</sub>D3, NF-&#x003ba;B activity in HaCaT and normal human keratinocytes was stimulated by two agents known to induce NF-&#x003ba;B activity, LPS or IL-1&#x003b1;. As shown in <xref ref-type="fig" rid="pone-0005988-g003">Figure 3B</xref>, both LPS and IL-1&#x003b1; increased NF-&#x003ba;B-driven luciferase activity in HaCaT cells and normal human keratinocytes, as compared to cells treated with vehicle (&#x0003c;0.01&#x00025; ethanol). We next examined the effects of 20(OH)D3 or 1,25(OH)<sub>2</sub>D3 on luciferase activity in HaCaT cells stimulated with LPS or IL-1&#x003b1;. Treatment with 20(OH)D3 or 1,25(OH)<sub>2</sub>D3 resulted in a statistically significant (p&#x0003c;0.05) decrease in NF-&#x003ba;B-driven luciferase expression in HaCaT cells stimulated by LPS or IL-1&#x003b1; with 20(OH)D3 and 1,25(OH)<sub>2</sub>D3 exhibiting similar potencies in inhibiting NF-&#x003ba;B activity. We than analyzed luciferase activity in cell extracts from human epidermal keratinocytes (HEKn), treated with 20(OH)D3 or 1,25(OH)<sub>2</sub>D3 and stimulated with LPS or IL-1&#x003b1;. Interestingly, the inhibition by 20(OH)D3 or 1,25(OH)<sub>2</sub>D3 of NF-&#x003ba;B activity was greater when the keratinocytes were stimulated with LPS as compared to IL-1&#x003b1;. 20(OH)D3 was slightly less potent in inhibiting NF-&#x003ba;B activity in keratinocytes when compared to 1,25(OH)<sub>2</sub>D3. Thus, despite the cell-type differences in the stimulation of NF-&#x003ba;B-dependent transcription activity by LPS versus IL-1&#x003b1;, 20(OH)D3 and 1,25(OH)<sub>2</sub>D3 inhibited NF-&#x003ba;B-dependent transcription.</p></sec><sec id="s2c"><title>20-Hydroxycholecalciferol inhibits translocation of the p65 NF&#x003ba;B protein induced by IL-1&#x003b1; in keratinocytes</title><p>To further characterize the inhibitory effect of 20(OH)D3 on NF-&#x003ba;B activity, we examined the cellular localization of the p65 NF-&#x003ba;B protein and the I&#x003ba;B&#x003b1; inhibitory protein in keratinocytes by fluorescent microscopy. As is usually observed in unstimulated cells, NF-&#x003ba;B is localized mainly in the cytoplasm with only minor nuclear staining detected. Stimulation of cells by IL-1&#x003b1; induced p65 translocation from the cytoplasm into the nucleus, indicative of the NF-&#x003ba;B activation. In contrast, treatment of cells with 20(OH)D3 nearly completely blocked the nuclear translocation of p65. In addition, there was a detectable increase in I&#x003ba;B&#x003b1; protein localized in the cytoplasm after treatment with 20(OH)D3 in comparison to vehicle-treated cells (<xref ref-type="fig" rid="pone-0005988-g004">Fig. 4</xref>). Similar results were obtained when HaCaT and normal keratinocytes were treated with 20(OH)D3 for 1, 4 or 24 hours (data not shown).</p><fig id="pone-0005988-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005988.g004</object-id><label>Figure 4</label><caption><title>20(OH)D3 inhibits the translocation of NF&#x003ba;B-p65 complex into the nucleus and increases the expression of I&#x003ba;B&#x003b1; in the cytosol of keratinocytes.</title><p>Primary human keratinocytes, third passage, were incubated for 4 h in KBM medium containing KGF with 100 nM 20(OH)D3 or ethanol vehicle, stimulated with IL-1&#x003b1; for 30 min and then fixed. Cells were stained with anti I&#x003ba;B&#x003b1; or NF&#x003ba;B-p65 antibody, followed by secondary antibody linked to FITC. Nuclei were stained red with propidium iodide. Cells were analyzed using fluorescent microscope at 40&#x000d7; magnification.</p></caption><graphic xlink:href="pone.0005988.g004"/></fig></sec><sec id="s2d"><title>20-hydroxycholecalciferol increases I&#x003ba;B&#x003b1; protein levels in keratinocytes</title><p>Since we demonstrated by various assays (EMSA, gene reporter assays, and immunofluorescence assays) that 20(OH)D3 inhibits NF-&#x003ba;B activity, we next examined the underlying mechanism responsible for this activity. In the classical NF-&#x003ba;B pathway, NF-&#x003ba;B activity is sequestered it in the cytoplasm by forming a complex with inhibitory I&#x003ba;B proteins. Moreover, as shown in <xref ref-type="fig" rid="pone-0005988-g004">figure 4</xref> 20(OH)D3 appears to increase cellular I&#x003ba;B levels as determined by immunofluorescent staining. To determine whether 20(OH)D3 affects the classical NF-&#x003ba;B pathway, the cellular levels of I&#x003ba;B&#x003b1; and the p65 NF&#x003ba;B were determined at various times after 20(OH)D3 addition to cells. 20(OH)D3 induced a time-dependent increase in I&#x003ba;B&#x003b1; levels in whole cell extracts of HEKn (<xref ref-type="fig" rid="pone-0005988-g005">Fig. 5A</xref>) and HaCaT keratinocytes (<xref ref-type="fig" rid="pone-0005988-g005">Fig. 5C</xref>). I&#x003ba;B&#x003b1; was increased within 1 hour of 20(OH)D3 treatment, and by 16 hours I&#x003ba;B&#x003b1; was diminished to the levels observed in untreated cells. Similar results were obtained when cells were treated with 1,25(OH)<sub>2</sub>D3. In contrast, cellular levels of p65 was unaffected by 20(OH)D3 treatment of keratinocytes. As shown <xref ref-type="fig" rid="pone-0005988-g005">figure 5B and 5D</xref>, statistically significant changes were observed for I&#x003ba;B&#x003b1; levels induced by 20(OH)D3 and 1,25(OH)<sub>2</sub>D3 expressed relative to &#x003b2;-actin (p&#x0003c;0.05).</p><fig id="pone-0005988-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005988.g005</object-id><label>Figure 5</label><caption><title>20(OH)D3 increases I&#x003ba;B&#x003b1; protein concentration in keratinocytes and has no effect on NF&#x003ba;B-p65.</title><p>Keratinocytes, HEKn and HaCaT were stimulated for the indicated times with 100 nM 20(OH)D3, and 100 nM 1,25(OH)<sub>2</sub>D3 (HEKn keratinocytes). Cells were lysed, whole cell extracts prepared, and equivalent amounts of protein were loaded onto polyacrylamide gels. Membranes were incubated with either anti-I&#x003ba;B&#x003b1;, anti-NF&#x003ba;B-p65 or anti &#x003b2;-actin (internal control) (A, C). Protein concentration expressed relative to &#x003b2;-actin was significantly different to the zero-time control for I&#x003ba;B&#x003b1; (p&#x0003c;0.05)(B, D). Results from three separate experiments are expressed as mean&#x000b1;STDEV.</p></caption><graphic xlink:href="pone.0005988.g005"/></fig><p>To further characterize the ability of 20(OH)D3 to inhibit NF-&#x003ba;B activity we stimulated NF-&#x003ba;B activity in normal human keratinocytes with IL-1&#x003b1; and determined I&#x003ba;B&#x003b1; levels in cytosolic extracts. We found that the concentration of I&#x003ba;B&#x003b1; levels were increased after treatment with 20(OH)D3 for 1 and 4 hours (<xref ref-type="fig" rid="pone-0005988-g006">Fig. 6A</xref>). Treatment of cells with 20(OH)D3 without IL-1&#x003b1; stimulation had a similar effect on I&#x003ba;B&#x003b1; levels. As shown <xref ref-type="fig" rid="pone-0005988-g006">figure 6B</xref>, statistically significant changes were observed for I&#x003ba;B&#x003b1; levels induced by 20(OH)D3 expressed relative to &#x003b2;-actin (p&#x0003c;0.05).</p><fig id="pone-0005988-g006" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005988.g006</object-id><label>Figure 6</label><caption><title>20(OH)D3 increases I&#x003ba;B&#x003b1; protein concentration in cytosolic extracts in keratinocytes.</title><p>Normal keratinocytes were treated with 100 nM 20(OH)D3 for 1 h and 4 h and then stimulated with or without IL-1&#x003b1; (10 ng/ml) for 30 min. Cells were lysed in lysis buffer and cytosolic extracts prepared. An equal amount of proteins was loaded onto the polyacrylamide gel. Membranes were incubated with antibodies: anti-I&#x003ba;B&#x003b1; and anti &#x003b2;-actin (internal control) (A). Protein concentration expressed relative to the concentration of &#x003b2;-actin is shown in (B). Results are expressed as mean&#x000b1;STDEV.</p></caption><graphic xlink:href="pone.0005988.g006"/></fig></sec><sec id="s2e"><title>20-Hydroxycholecalciferol stimulates I&#x003ba;B&#x003b1; mRNA expression, but does not affect NF- &#x003ba;B mRNA expression in keratinocytes</title><p>To determine whether the increased I&#x003ba;B&#x003b1; protein levels in cells treated with 20(OH)D3 resulting from increased I&#x003ba;B&#x003b1; mRNA expression, we measured I&#x003ba;B mRNA levels by quantitative real time PCR (qPCR). As shown in <xref ref-type="fig" rid="pone-0005988-g007">figure 7</xref> the I&#x003ba;B&#x003b1;-mRNA levels were significantly increased after 20(OH)D3 treatment of HaCaT and normal human keratinocytes. The induction by 20(OH)D3 of I&#x003ba;B&#x003b1; mRNA expression was greater in HaCaT cells than in normal keratinocytes. The effect was already detected 1 hour after treatment and returned to basal levels by 24 hours in normal keratinocytes, while the induction of I&#x003ba;B&#x003b1; mRNA persisted up to 24 hours in HaCaT cells. Moreover, the effects of 1,25(OH)<sub>2</sub>D3 on I&#x003ba;B&#x003b1; mRNA levels were qualitatively similar to those noted for 20(OH)D3. In contrast, mRNA levels of the p50 and p65 NF-&#x003ba;B subunits were unaffected by treatment with either 1,25(OH)<sub>2</sub>D3 or 20OHD3 (data not shown).</p><fig id="pone-0005988-g007" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005988.g007</object-id><label>Figure 7</label><caption><title>20(OH)D3 increases mRNA levels of I&#x003ba;B&#x003b1; in keratinocytes.</title><p>HEKn and HaCaT keratinocytes were treated with 100 nM 20(OH)D3 or 1,25(OH)<sub>2</sub>D3 or vehicle for the indicated period of time. Cells were then lysed and total RNA extracted. mRNA levels for I&#x003ba;B&#x003b1; were measured using reagents for RTPCR according to the manufacturer's protocol (Roche Applied Science, Manheim, Germany) and normalized relative to Cyclophylin B RNA. Data are presented as mean&#x000b1;STD (n&#x0200a;&#x0003d;&#x0200a;3) &#x0002a;p&#x0003c;0.05 versus control, or &#x0002a;&#x0002a;p&#x0003c;0.01 versus control. Time response in the expression of mRNA was shown for NF&#x003ba;BI (I&#x003ba;B&#x003b1;) in both cells.</p></caption><graphic xlink:href="pone.0005988.g007"/></fig></sec><sec id="s2f"><title>20-hydroxycholecalciferol requires VDR expression for its action on the NF-&#x003ba;B pathway in keratinocytes</title><p>We previously demonstrated that the action of 20(OH)D3 on human keratinocytes is dependent on VDR expression <xref ref-type="bibr" rid="pone.0005988-Zbytek1">&#x0005b;15&#x0005d;</xref>. Therefore, we examined whether the effect of 20(OH)D3 on the NF-&#x003ba;B pathway was also VDR-dependent. Human keratinocytes were transiently transfected with siRNA to knock-down VDR expression, treated with 20(OH)D3 or vehicle (ethanol) and RNA isolated for gene expression analysis by qPCR In parallel experiments cell extracts were analyzed for protein expression by western blot. As shown in <xref ref-type="fig" rid="pone-0005988-g008">figure 8A</xref> transfection of keratinocytes with VDR siRNA knocked-down the levels of the vitamin D receptor by approximately &#x0223c;80&#x00025;. Most importantly, knock-down of the VDR in keratinocytes completely blocked I&#x003ba;B&#x003b1; mRNA induction by 20(OH)D3 treatment. In contrast, 20(OH)D3 treatment induced a &#x0223c;2 fold increase in I&#x003ba;B&#x003b1; mRNA in cells transfected with scrambled siRNA (<xref ref-type="fig" rid="pone-0005988-g008">Fig. 8B</xref>). The mRNA levels for p50 and p65 NF-&#x003ba;B proteins were unaffected by VDR knockdown (data not shown for p50). To further test the ability of VDR knockdown on NF&#x003ba;B translocation, we transfected cells with scrambled or VDR siRNA and treated them with 20(OH)D3, and than examined the cellular localization of the p65 NF-&#x003ba;B protein and the I&#x003ba;B&#x003b1; inhibitory protein in keratinocytes by fluorescent microscopy. In summary, significantly less I&#x003ba;B&#x003b1; protein was localized in the cytoplasm after 20(OH)D3 treatment of VDR knockdown cells as compared with scrambled siRNA-treansfected cells (<xref ref-type="fig" rid="pone-0005988-g008">Fig. 8D</xref>). 20(OH)D3 treatment of cells nearly completely blocked the nuclear translocation of p65. In contrast, 20(OH)D3 treatment of VDR knockdown cells did not block the nuclear translocation of p65 (<xref ref-type="fig" rid="pone-0005988-g008">Figure 8E</xref>).</p><fig id="pone-0005988-g008" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005988.g008</object-id><label>Figure 8</label><caption><title>Silencing of the VDR in human keratinocytes attenuates the effects of 20(OH)D3 on I&#x003ba;B&#x003b1; or NF&#x003ba;B p65 (RelA) expression and intracellular transolaction.</title><p>Keratinocytes were transfected with 2 nM scrambled or VDR siRNA and incubated with 100 nM 20(OH)D3 or vehicle (ethanol) for 4 h. Cells were lysed after treatment and total RNA extracted. VDR mRNA (A), I&#x003ba;B&#x003b1; mRNA (B) and NF&#x003ba;B p65 (RelA) (C) levels were measured using reagents for RTPCR according to manufacturer's protocol (Roche Applied Science, Manheim, Germany) and normalized relative to Cyclophylin B RNA. Data are presented as mean&#x000b1;STD (n&#x0200a;&#x0003d;&#x0200a;3) &#x0002a;p&#x0003c;0.05 versus control, or &#x0002a;&#x0002a;p&#x0003c;0.01 versus control. Levels of VDR and &#x003b2;-actin were assessed 24 h after transfection with VDR or scrambled siRNA, by western blotting of whole-cell extracts (A). 24 h after transfection with 2 nM scrambled or VDR siRNA, primary human keratinocytes were also incubated for 4 h in KBM medium containing KGF with 100 nM 20(OH)D3 or ethanol (vehicle), then fixed. Cells were stained with anti-I&#x003ba;B&#x003b1; antibody (green), followed by secondary antibody linked to FITC. Nuclei were stained red with propidium iodide (D). Another set of cells was stained with anti-p65 (green) (E). Cells were analyzed using a fluorescent microscope at 20&#x000d7; magnification.</p></caption><graphic xlink:href="pone.0005988.g008"/></fig></sec></sec><sec id="s3"><title>Discussion</title><p>We have previously shown that 20(OH)D3 is a product of vitamin D3 metabolism by cytochrome P450scc (see <xref ref-type="fig" rid="pone-0005988-g001">Fig. 1</xref>) <xref ref-type="bibr" rid="pone.0005988-Slominski2">&#x0005b;7&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-Tuckey2">&#x0005b;10&#x0005d;</xref>. Moreover, 20(OH)D3 has significant biological activity in human keratinocytes, as it inhibits their proliferation and stimulates their differentiation <xref ref-type="bibr" rid="pone.0005988-Zbytek1">&#x0005b;15&#x0005d;</xref>. In the present study we demonstrate that 20(OH)D3 is a potent inhibitor of NF-&#x003ba;B activity. Moreover, 20(OH)D3 treatment also increases I&#x003ba;B&#x003b1; protein levels through induction of I&#x003ba;B&#x003b1; mRNA expression. I&#x003ba;B&#x003b1; induction by 20(OH)D3 requires VDR expression, indicating that 20(OH)D3 acts through the classical vitamin D and NF&#x003ba;B regulatory pathways.</p><p>The inhibitory effect of 20(OH)D3 on NF-&#x003ba;B activity in keratinocytes was shown by several complementary approaches including NF-&#x003ba;B dependent DNA binding assays, NF&#x003ba;B-driven reporter gene activity assays, as well as western blotting and immunofluorescence analysis of the translocation of p65 NF-&#x003ba;B subunit from cytoplasm into the nucleus. The inhibitory effect of 20(OH)D3 was rapid (within 30 minutes), reached a maximum by 4 hr after addition, and remained detectable as long as 24 hr after addition. The inhibitory effect of 20(OH)D3 on NF-&#x003ba;B-dependent transcriptional activity by luciferase reporter-gene analysis (<xref ref-type="fig" rid="pone-0005988-g003">Fig. 3</xref>) paralleled the time course of 20(OH)D3 inhibition of NF-&#x003ba;B-dependent DNA binding activity by EMSA (<xref ref-type="fig" rid="pone-0005988-g002">Fig. 2</xref>). The inhibitory effect of 20(OH)D3 on NF-&#x003ba;B was greater in normal human keratinocytes as compared to the effect in HaCaT keratinocytes. This discrepancy might be secondary to the immortalization of HaCaT cells, which might render them less sensitive to 20(OH)D3 treatment. Moreover, 20(OH)D3 had similar potency to that of the well characterized 1,25(OH)<sub>2</sub>D3 in inhibiting NF-&#x003ba;B activity in keratinocytes (no statistically significant difference). The vitamin D analogs, 1,25(OH)<sub>2</sub>D3 and 1,24(OH)<sub>2</sub>D3, have been previously reported to inhibit NF-&#x003ba;B activity <xref ref-type="bibr" rid="pone.0005988-CohenLahav2">&#x0005b;57&#x0005d;</xref>. Also, 1,25(OH)<sub>2</sub>D3 has been previously shown to regulate NF-&#x003ba;B DNA binding activity in human keratinocytes through an increase in I&#x003ba;B&#x003b1; expression <xref ref-type="bibr" rid="pone.0005988-Riis1">&#x0005b;55&#x0005d;</xref>. In this study, 1,25(OH)<sub>2</sub>D3 inhibited NF-&#x003ba;B binding to the IL-8 &#x003ba;B binding sequence more potently than binding to the p53 &#x003ba;B binding sequence. This selectivity may be mediated through an increased I&#x003ba;B&#x003b1; expression, indicating that vitamin D analogues may exert their immunomodulatory effects through NF-&#x003ba;B regulated proinflammatory cytokines and chemokines. In our study we tested the effect of the novel analog of vitamin D3, 20(OH)D3, not only on NF-&#x003ba;B activity, but also on protein and mRNA levels, as well as the role of VDR in the effect of 20(OH)D3 on NF-&#x003ba;B. We clearly demonstrate that 20(OH)D3 inhibits NF-&#x003ba;B activity with potency similar to that of calcitriol (1,25(OH)<sub>2</sub>D3, the endogenous active form of vitamin D3). The mechanism of action or 20(OH)D3 appears to be very similar to that of 1,25(OH)<sub>2</sub>D3. The hydroxyl group of 20(OH)D3 is attached at the C20 position <xref ref-type="bibr" rid="pone.0005988-Slominski2">&#x0005b;7&#x0005d;</xref>; which is interesting since the attachment at C1 is considered to be required for full biological activity and calcemic effects <xref ref-type="bibr" rid="pone.0005988-Holick1">&#x0005b;2&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-Holick2">&#x0005b;5&#x0005d;</xref>.</p><p>To further characterize the action of 20(OH)D3 on inhibiting NF-&#x003ba;B activity we used known stimulators of the NF-&#x003ba;B pathway, LPS and IL-1&#x003b1; <xref ref-type="bibr" rid="pone.0005988-Karin1">&#x0005b;64&#x0005d;</xref>. Keratinocytes can produce a plethora of cytokines including interleukin (IL)-1 and tumor necrosis factor &#x003b1; (TNF) (reviewed in <xref ref-type="bibr" rid="pone.0005988-Grone1">&#x0005b;37&#x0005d;</xref>). IL-1 activates keratinocytes and promotes their proliferation and migration. Also, LPS is considered as a potent NF-&#x003ba;B stimulator <xref ref-type="bibr" rid="pone.0005988-Li2">&#x0005b;65&#x0005d;</xref>. In the present study, 20(OH)D3 was found to attenuate NF-&#x003ba;B transcriptional activity induced by both LPS or IL-1 in HaCaT cells and primary keratinocytes, and exhibited a similar potency to 1,25(OH)<sub>2</sub>D3. Interestingly, in normal keratinocytes the inhibition of NF-&#x003ba;B activity stimulated with IL-1&#x003b1; by vitamin D3 hydroxyderivatives was less pronounced then the inhibition of activity stimulated with LPS. This indicates that immortalization changes the responsiveness of keratinocytes to various stimuli, as it has been demonstrated in case of neuropeptides <xref ref-type="bibr" rid="pone.0005988-Zbytek2">&#x0005b;63&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-Zbytek3">&#x0005b;66&#x0005d;</xref>. Nonetheless, both 20(OH)D3 and 1,25(OH)<sub>2</sub>D3 inhibit NF-&#x003ba;B activity in keratinocytes induced by recognized proinflammatory stimuli.</p><p>Stimulation of NF-&#x003ba;B activity by LPS and IL-1&#x003b1; does not alter the action of 20(OH)D3 on NF-&#x003ba;B activity, since 20(OH)D3 treatment of cells with or without exogenous stimulation had similar effects on p65 localization and I&#x003ba;B&#x003b1; levels. Although NF-&#x003ba;B can be activated through both classical and alternative signaling pathways, previous studies have indicated that IL-1 and LPS activate NF-&#x003ba;B through the classical signaling pathway <xref ref-type="bibr" rid="pone.0005988-Pomerantz1">&#x0005b;46&#x0005d;</xref>. In this general pathway, p50&#x02236;p65 dimers are sequestered in the cytoplasm by I&#x003ba;B proteins. LPS and IL-1 stimulate I&#x003ba;B kinase activity, resulting in the subsequent I&#x003ba;B phosphorylation and ubiquitinylation. Then I&#x003ba;B is targeted for proteosomal degradation, which allows p50&#x02236;p65 dimers to translocate to the nucleus, bind to DNA and activate the transcription of NF-&#x003ba;B-dependent genes. Consistent with this general pathway we show that both LPS and IL-1 stimulate NF-&#x003ba;B transcriptional activity as well as result in I&#x003ba;B degradation. Most importantly, we show that 20(OH)D3 acts as an immunosuppressive agent in human keratinocytes by blocking the activation of this signaling pathway by both IL-1 and LPS. 20(OH)D3 not only inhibits the translocation of the p65 NF-&#x003ba;B protein from cytoplasm to nucleus in keratinocytes, but also increases the cellular levels of the inhibitory NF-&#x003ba;B protein, I&#x003ba;B, thus sequestering the NF-&#x003ba;B in the cytoplasm as transcriptionally inactive NF-&#x003ba;B/I&#x003ba;B complexes. Since recent studies demonstrate that activation of the alternative NF-&#x003ba;B pathway can also lead to the translocation of p65-containing dimers into the nucleus <xref ref-type="bibr" rid="pone.0005988-Du1">&#x0005b;42&#x0005d;</xref>, our data cannot exclude the possibility that 20(OH)D3 also blocks this signaling pathway as well. Detailed analysis of the alternative signaling pathway will be the subject of future studies.</p><p>In previous studies we showed that the action of 20(OH)D3 on proliferation and differentiation in keratinocytes requires VDR expression <xref ref-type="bibr" rid="pone.0005988-Zbytek1">&#x0005b;15&#x0005d;</xref>. In the present study we find that silencing VDR expression in keratinocytes blocks the inhibitory actions of 20(OH)D3 on NF-&#x003ba;B activity (<xref ref-type="fig" rid="pone-0005988-g008">Fig. 8</xref>). Therefore, our data indicates that both 20(OH)D3 (novel ligand) and 1,25(OH)<sub>2</sub>D3 (classical ligand) suppress NF-&#x003ba;B activity through a VDR-mediated signaling pathway. Although the mechanism of this pathway in inhibiting NF-&#x003ba;B activity requires more in-depth analysis, our studies demonstrate that 20(OH)D3 can induce anti-inflammatory actions similar to those mediated by calcitriol (1,25(OH)<sub>2</sub>D3) via the VDR-mediated inhibition of NF-&#x003ba;B activity. Interestingly vitamin D analogues are now widely used drugs for the treatment of psoriasis, an inflammatory and hyperproliferative dermatoses (reviewed in <xref ref-type="bibr" rid="pone.0005988-Masuda1">&#x0005b;49&#x0005d;</xref>). Therefore, we believe that 20(OH)D3 holds promise as a novel therapeutic agent in the prevention and therapy of inflammatory, auto-immune and hyperproliferative skin diseases.</p><p>Recently, new and important immunomodulatory effects of vitamin D analogs have been characterized, especially those for 1,25(OH)<sub>2</sub>D3 <xref ref-type="bibr" rid="pone.0005988-Lehmann1">&#x0005b;1&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-Holick4">&#x0005b;25&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-Reichrath1">&#x0005b;67&#x0005d;</xref>. Inhibitors targeting the NF-&#x003ba;B signaling pathway effectively suppress NF-&#x003ba;B activity, protect and relieve inflammatory symptoms, and induce apoptosis of tumor cells. NF-&#x003ba;B represents an attractive drug target for therapy of inflammatory and autoimmune disorders, as well as for cancer. Thus, 20(OH)D3 is a new powerful analog of vitamin D3 that is produced by enzymatic activity of CYP11A1 <xref ref-type="bibr" rid="pone.0005988-Slominski2">&#x0005b;7&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-Tuckey2">&#x0005b;10&#x0005d;</xref>, and have pleiotropic activities through its ability to modulate the NF-&#x003ba;B signaling pathway as illustrated in <xref ref-type="fig" rid="pone-0005988-g009">figure 9</xref>. Increased expression of I&#x003ba;B&#x003b1; and inhibition of NF-&#x003ba;B activity in keratinocytes induced by 20(OH)D3 may be one mechanism by which this (potentially endogenous) vitamin D analog could exert beneficial effects in inflammatory and auto-immune disorders.</p><fig id="pone-0005988-g009" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005988.g009</object-id><label>Figure 9</label><caption><title>A schematic representation of the effects of 20(OH)D3 on NF&#x003ba;B signal transduction in keratinocytes.</title></caption><graphic xlink:href="pone.0005988.g009"/></fig></sec><sec sec-type="materials|methods" id="s4"><title>Materials and Methods</title><sec id="s4a"><title>Cell culture</title><p>Immortalized human keratinocytes (HaCaT), which are frequently used for studies on biological effect of 1,25(OH)<sub>2</sub>D3 <xref ref-type="bibr" rid="pone.0005988-Bikle5">&#x0005b;30&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-Lehmann3">&#x0005b;68&#x0005d;</xref>, were cultured in Dulbecco's Modified Eagle Medium supplemented with glucose, L-glutamine, pyridoxine hydrochloride (Cell Grow), 5&#x00025; fetal bovine serum (Sigma) and 1&#x00025; penicillin/streptomycin/amphotericin antibiotic solution (Sigma) <xref ref-type="bibr" rid="pone.0005988-Slominski1">&#x0005b;6&#x0005d;</xref>. In order to eliminate potential interference by sterols present in the serum <xref ref-type="bibr" rid="pone.0005988-Gurlek1">&#x0005b;69&#x0005d;</xref>, 5&#x00025; charcoal/dextran-treated bovine serum (HyClone) was used to test the effects of active forms of vitamin D. In addition, cells were serum-deprived for 24 h before treatment. Normal human epidermal keratinocytes were isolated from neonatal foreskin (HEKn) and grown in KGM medium supplemented with KGF (Lonza) on collagen-coated plates <xref ref-type="bibr" rid="pone.0005988-Zbytek1">&#x0005b;15&#x0005d;</xref>. For experiments cells in their third passage were used.</p></sec><sec id="s4b"><title>Immunofluorescent staining</title><p>HEKn cells were seeded onto cover glasses in 6-well plate and treated with 100 nM of 20(OH)D3 for 24 h. Control cells were treated with solvent (&#x0003c;0.1&#x00025; ethanol). After treatment cells were washed in PBS and fixed in 4&#x00025; paraformaldehyde. Cells were than incubated in permeabilizing solution (0.2&#x00025; Triton-X 100 in PBS) for 5 min, washed with PBS and blocked in 2&#x00025; BSA for 30 min. Primary antibody, either goat anti-rabbit-p65 (1&#x02236;100) or goat anti-rabbit-I&#x003ba;B (1&#x02236;100) in 1&#x00025; BSA, was added to the cells and incubated overnight at 4&#x000b0;C. After extensive washing in PBS, cells were incubated in the secondary antibody solution comprising goat-anti-rabbit-Alexa Fluor 488 (Invitrogen, 1&#x02236;500 in PBS) and incubated for 1 h at room temperature in the dark. Cells on cover glass were washed and mounted with mounting medium containing propidium iodine (Vectashield). Stained cells were analyzed using a fluorescent microscope at 40&#x000d7; magnification.</p></sec><sec id="s4c"><title>Transfection and Reporter assay</title><p>The constructs pLuc, pHRLTK and NF&#x003ba;B-Luc have been described previously <xref ref-type="bibr" rid="pone.0005988-Pisarchik1">&#x0005b;70&#x0005d;</xref>. According to our protocols <xref ref-type="bibr" rid="pone.0005988-Zbytek2">&#x0005b;63&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-Zbytek3">&#x0005b;66&#x0005d;</xref>, HaCaT and normal epidermal keratinocytes were transfected using Lipofectamine Plus (Invitrogen, Carlsbad, CA) in DMEM or KGM medium, with firefly luciferase reporter gene plasmid and with phRL-TK (expresses Renilla luciferase and serves as normalization control; Promega, Madison, WI). At 24 hr after transfection, the medium was changed and the cells were treated with the vitamin D3 derivatives or vehicle (&#x0003c;0.1&#x00025; ethanol) for 0.5, 1, 4, 16 and 24 h. Following this protocol, cells were also treated with 10 ng/ml interleukin 1&#x003b1; (IL-1&#x003b1;) (Sigma) or 1 &#x000b5;g/ml LPS (Sigma) for 30 minutes. The Firefly luciferase and Renilla luciferase signals were recorded with a TD-20/20 luminometer (Turner Designs, Sunnyvale, CA); background luminescence was subtracted and the resulting promoter specific firefly signal was divided by the Renilla signal (proportional to the number of transfected cells). The values obtained were calculated relative to control (untreated) cells, and expressed as relative fold change.</p></sec><sec id="s4d"><title>siRNA transfection</title><p>Keratinocytes were transfected with 2 nM VDR or scrambled siRNA (Dharmacon), on-Target plus smart pool human VDR or on-Target plus siControl non-targeting pool, using lipofectamine plus (Invitrogen) in DMEM medium. Twenty four hours after transfection, cells were treated for an additional 4 h with 100 nM 20(OH)D3 or vehicle (ethanol), mRNA was isolated and used for gene expression analysis or cells were stained for I&#x003ba;B&#x003b1; or NF&#x003ba;B p65 and examined for protein localization by fluorescent microscopy.</p></sec><sec id="s4e"><title>Preparation of cell lysates</title><p>Cells were treated with 20(OH)D3 or 1,25(OH)<sub>2</sub>D3, and whole cell lysates were prepared as described previously <xref ref-type="bibr" rid="pone.0005988-Hanissian1">&#x0005b;71&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005988-Hanissian2">&#x0005b;72&#x0005d;</xref>. Cells were resuspended in RIPA buffer containing protease inhibitor cocktail (Sigma) and PMSF. Nuclear extracts were prepared as described previously <xref ref-type="bibr" rid="pone.0005988-Zbytek4">&#x0005b;73&#x0005d;</xref>. In brief, HaCaT or normal human keratinocytes were treated with 100 nM 20(OH)D3 for 0, 0.5, 1, 4, 16 or 24 h, and then stimulated with or without interleukin 1&#x003b1; (10 ng/ml) for an additional 30 min. The cells were harvested, pelleted and resuspended in STM buffer (20 mM Tris-HCl, 250 mM sucrose and 1.1 mM MgCl<sub>2</sub>). The nuclear pellet was resuspended in 30 &#x000b5;l nuclear extraction buffer containing 0.4 M KCl, 5 mM 2-mercaptoethanol and protease inhibitor cocktail (1&#x02236;100 dilution, Sigma) in STM buffer, and incubated on ice for 30 min with intermittent shaking and then centrifuged at 14,000&#x000d7;g for 20 min at 4&#x000b0;C. The protein content in the supernatant was quantified using the Bradford protein assay kit <xref ref-type="bibr" rid="pone.0005988-Pavicevic1">&#x0005b;74&#x0005d;</xref>. Cytosolic extracts were prepared as described previously with minor modifications <xref ref-type="bibr" rid="pone.0005988-Riis1">&#x0005b;55&#x0005d;</xref>. Cell pellets were resuspended in hypotonic buffer (10 mM HEPES pH 7.9, 10 mM KCl, 0.2 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 0.5&#x00025; NP40, protease inhibitor cocktail (Sigma) and 20 mM PMSF), and after a 20 min of incubation on ice the suspension was centrifuged at 4&#x000b0;C for 10 minutes at 5,000&#x000d7;g. The centrifuged supernatant was considered the cytosolic extract.</p><p>The levels of I&#x003ba;B&#x003b1;, the p65 NF-&#x003ba;B protein, and &#x003b2;-actin were assessed by immunoblotting. Primary antibodies used were the rabbit polyclonal antibodies directed against I&#x003ba;B-&#x003b1; (Santa Cruz, 1&#x02236;500 dilution); p65 (Santa Cruz, 1&#x02236;500 dilution) and &#x003b2;-actin-peroxidase (Sigma, 1&#x02236;5000 dilution). The secondary antibody used was anti rabbit IgG (Santa Cruz, 1&#x02236;7,000 dilution) and anti-mouse IgG (Santa Cruz, 1&#x02236;5,000) conjugated to horseradish peroxidase. Signals were detected using ECL kit Supersignal West Pico Chemiluminescent Substrate (Pierce). The intensity of bands was measured using ImageJ Software. Results for whole cell and cytosolic protein levels were expressed relative to &#x003b2;-actin levels <xref ref-type="bibr" rid="pone.0005988-Pavicevic1">&#x0005b;74&#x0005d;</xref>. Levels of VDR and &#x003b2;-actin 24 h after VDR siRNA transfection were assessed in western blots with (VDR(D-6)) antibody (Santa Cruz, 1&#x02236;400).</p></sec><sec id="s4f"><title>Electrophoretic mobility shift assay (EMSA)</title><p>DNA binding activity was determined by EMSA using a consensus NF-&#x003ba;B IRDye-labeled oligonucleotide probe (LI-COR). The DNA binding reaction consisted of 2.5 to 5 &#x000b5;g of the nuclear extract, the NF-&#x003ba;B probe and gel shift binding buffer containing of 2.5 mM DTT, 0.25&#x00025; Tween-20 and 0.25 mg/ml poly(dI) &#x02236;poly(dC). The reaction was carried out at room temperature in the dark for 30 min. For supershift assays 1 &#x000b5;g of p65 or p50 antibody (gift of the NCI Preclinical Repository) was added to the nuclear extract prior to DNA binding and incubated for 30 min at 4&#x000b0;C. Orange loading dye was added to samples which were loaded on pre-run 5&#x00025; TBE gels and run at 70 V for 2 h. The gel was scanned using an Odyssey Infrared Imaging System (LI-COR, Inc,. Lincoln, NE).</p></sec><sec id="s4g"><title>Real-time RT PCR</title><p>The RNA from HaCaT and normal keratinocytes treated with 20(OH)D3 or 1,25(OH)<sub>2</sub>D3 was isolated using Absolutely RNA Miniprep Kit (Stratagen). Reverse transcription (100 ng/reaction) was performed with Transcriptor First Strand cDNA Synthesis Kit (Roche). Real-time PCR was performed using cDNA diluted 10-fold in sterile water and a TaqMan PCR Master Mix (n&#x0200a;&#x0003d;&#x0200a;3). Reactions were performed at 50 &#x000b0;C for 2 min, 95 &#x000b0;C for 10 min and than 50 cycles of 95 &#x000b0;C for 15 s, 60 &#x000b0;C for 1 min). The primers and probes were designed with universal probe library (Roche): I&#x003ba;B&#x003b1; primers (left: <named-content content-type="gene">GTCAAGGAGCTGCAGGAGAT</named-content> and right: <named-content content-type="gene">GATGGCCAAGTGCAGGAA</named-content>), probe #38; NF&#x003ba;B1 primers (left: <named-content content-type="gene">ACCCTGACCTTGCCTATTTG</named-content> and right: <named-content content-type="gene">AGCTCTTTTTCCCGATCTCC</named-content>), probe #39; and RelA primers (left: <named-content content-type="gene">CGGGATGGCTTCTATGAGG</named-content> and right: <named-content content-type="gene">CTCCAGGTCCCGCTTCTT</named-content>), probe #47; VDR primers (left: <named-content content-type="gene">CTTACCTGCCCCCTGCTC</named-content> and right <named-content content-type="gene">AGGGTCAGGCAGGGAAGT</named-content>), probe #58. The data was collected on a Roche Light Cycler 480. The amounts of product were compared to Cyclophilin B using a comparative C<sub>T</sub> method.</p></sec><sec id="s4h"><title>Statistical analysis</title><p>Data are presented as means&#x000b1;STDEV and were analyzed with Student's t-test (for 2 groups) and one-way Anova with appropriate post-hoc test (for more than 2 groups) using Excel (Microsoft) and Prism 4.00 (GraphPad Software, San Diego), respectively. Statistically significant differences are denoted with asterisks: &#x0002a;P&#x0003c;0.05, &#x0002a;&#x0002a;P&#x0003c;0.001.</p></sec></sec></body><back><ack><p>We thank Dr William Taylor at the Molecular Resource Center, University of Tennessee Health Science Center for helpful comments regarding qPCR experiments. We also thank Dr Irina Nosrat for help in fluorescent microscopy.</p></ack><ref-list><title>References</title><ref id="pone.0005988-Lehmann1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lehmann</surname><given-names>B</given-names></name><name><surname>Querings</surname><given-names>K</given-names></name><name><surname>Reichrath</surname><given-names>J</given-names></name></person-group><year>2004</year><article-title>Vitamin D and skin: new aspects for dermatology.</article-title><source>Exp Dermatol</source><volume>13</volume><issue>Suppl 4</issue><fpage>11</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">15507106</pub-id></citation></ref><ref id="pone.0005988-Holick1"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Holick</surname><given-names>MF</given-names></name></person-group><year>2003</year><article-title>Vitamin D: A millenium perspective.</article-title><source>J Cell Biochem</source><volume>88</volume><fpage>296</fpage><lpage>307</lpage><pub-id pub-id-type="pmid">12520530</pub-id></citation></ref><ref id="pone.0005988-Bikle1"><label>3</label><citation citation-type="other"><collab>Bikle</collab><year>2006</year><article-title>Vitamin D: production, metabolism and mechanism of action.</article-title><comment><ext-link ext-link-type="uri" xlink:href="http://www.endotext.com">www.endotext.com</ext-link></comment></citation></ref><ref id="pone.0005988-Webb1"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Webb</surname><given-names>AR</given-names></name></person-group><year>2006</year><article-title>Who, what, where and when-influences on cutaneous vitamin D synthesis.</article-title><source>Prog Biophys Mol Biol</source><volume>92</volume><fpage>17</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">16766240</pub-id></citation></ref><ref id="pone.0005988-Holick2"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Holick</surname><given-names>MF</given-names></name><name><surname>Clark</surname><given-names>MB</given-names></name></person-group><year>1978</year><article-title>The photobiogenesis and metabolism of vitamin D.</article-title><source>Fed Proc</source><volume>37</volume><fpage>2567</fpage><lpage>2574</lpage><pub-id pub-id-type="pmid">212325</pub-id></citation></ref><ref id="pone.0005988-Slominski1"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Slominski</surname><given-names>A</given-names></name><name><surname>Semak</surname><given-names>I</given-names></name><name><surname>Zjawiony</surname><given-names>J</given-names></name><name><surname>Wortsman</surname><given-names>J</given-names></name><name><surname>Gandy</surname><given-names>MN</given-names></name><etal/></person-group><year>2005</year><article-title>Enzymatic metabolism of ergosterol by cytochrome p450scc to biologically active 17alpha,24-dihydroxyergosterol.</article-title><source>Chem Biol</source><volume>12</volume><fpage>931</fpage><lpage>939</lpage><pub-id pub-id-type="pmid">16125105</pub-id></citation></ref><ref id="pone.0005988-Slominski2"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Slominski</surname><given-names>A</given-names></name><name><surname>Semak</surname><given-names>I</given-names></name><name><surname>Zjawiony</surname><given-names>J</given-names></name><name><surname>Wortsman</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><etal/></person-group><year>2005</year><article-title>The cytochrome P450scc system opens an alternate pathway of vitamin D3 metabolism.</article-title><source>Febs J</source><volume>272</volume><fpage>4080</fpage><lpage>4090</lpage><pub-id pub-id-type="pmid">16098191</pub-id></citation></ref><ref id="pone.0005988-Slominski3"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Slominski</surname><given-names>A</given-names></name><name><surname>Zjawiony</surname><given-names>J</given-names></name><name><surname>Wortsman</surname><given-names>J</given-names></name><name><surname>Semak</surname><given-names>I</given-names></name><name><surname>Stewart</surname><given-names>J</given-names></name><etal/></person-group><year>2004</year><article-title>A novel pathway for sequential transformation of 7-dehydrocholesterol and expression of the P450scc system in mammalian skin.</article-title><source>Eur J Biochem</source><volume>271</volume><fpage>4178</fpage><lpage>4188</lpage><pub-id pub-id-type="pmid">15511223</pub-id></citation></ref><ref id="pone.0005988-Tuckey1"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tuckey</surname><given-names>RC</given-names></name><name><surname>Janjetovic</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Nguyen</surname><given-names>MN</given-names></name><name><surname>Zmijewski</surname><given-names>MA</given-names></name><etal/></person-group><year>2008</year><article-title>Metabolism of 1alpha-hydroxyvitamin D3 by cytochrome P450scc to biologically active 1alpha,20-dihydroxyvitamin D3.</article-title><source>J Steroid Biochem Mol Biol</source></citation></ref><ref id="pone.0005988-Tuckey2"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tuckey</surname><given-names>RC</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Zjawiony</surname><given-names>JK</given-names></name><name><surname>Zmijewski</surname><given-names>MA</given-names></name><name><surname>Nguyen</surname><given-names>MN</given-names></name><etal/></person-group><year>2008</year><article-title>Pathways and products for the metabolism of vitamin D3 by cytochrome P450scc.</article-title><source>Febs J</source><volume>275</volume><fpage>2585</fpage><lpage>2596</lpage><pub-id pub-id-type="pmid">18410379</pub-id></citation></ref><ref id="pone.0005988-Tuckey3"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tuckey</surname><given-names>RC</given-names></name><name><surname>Nguyen</surname><given-names>MN</given-names></name><name><surname>Slominski</surname><given-names>A</given-names></name></person-group><year>2008</year><article-title>Kinetics of vitamin D3 metabolism by cytochrome P450scc (CYP11A1) in phospholipid vesicles and cyclodextrin.</article-title><source>Int J Biochem Cell Biol</source></citation></ref><ref id="pone.0005988-Slominski4"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Slominski</surname><given-names>A</given-names></name><name><surname>Semak</surname><given-names>I</given-names></name><name><surname>Wortsman</surname><given-names>J</given-names></name><name><surname>Zjawiony</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><etal/></person-group><year>2006</year><article-title>An alternative pathway of vitamin D metabolism. Cytochrome P450scc (CYP11A1)-mediated conversion to 20-hydroxyvitamin D2 and 17,20-dihydroxyvitamin D2.</article-title><source>Febs J</source><volume>273</volume><fpage>2891</fpage><lpage>2901</lpage><pub-id pub-id-type="pmid">16817851</pub-id></citation></ref><ref id="pone.0005988-Tuckey4"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tuckey</surname><given-names>RC</given-names></name></person-group><year>2005</year><article-title>Progesterone synthesis by the human placenta.</article-title><source>Placenta</source><volume>26</volume><fpage>273</fpage><lpage>281</lpage><pub-id pub-id-type="pmid">15823613</pub-id></citation></ref><ref id="pone.0005988-Lehmann2"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lehmann</surname><given-names>B</given-names></name></person-group><year>2005</year><article-title>The vitamin D3 pathway in human skin and its role for regulation of biological processes.</article-title><source>Photochem Photobiol</source><volume>81</volume><fpage>1246</fpage><lpage>1251</lpage><pub-id pub-id-type="pmid">16162035</pub-id></citation></ref><ref id="pone.0005988-Zbytek1"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zbytek</surname><given-names>B</given-names></name><name><surname>Janjetovic</surname><given-names>Z</given-names></name><name><surname>Tuckey</surname><given-names>RC</given-names></name><name><surname>Zmijewski</surname><given-names>MA</given-names></name><name><surname>Sweatman</surname><given-names>TW</given-names></name><etal/></person-group><year>2008</year><article-title>20-Hydroxyvitamin D3, a Product of Vitamin D3 Hydroxylation by Cytochrome P450scc, Stimulates Keratinocyte Differentiation.</article-title><source>J Invest Dermatol</source></citation></ref><ref id="pone.0005988-Deeb1"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Deeb</surname><given-names>KK</given-names></name><name><surname>Trump</surname><given-names>DL</given-names></name><name><surname>Johnson</surname><given-names>CS</given-names></name></person-group><year>2007</year><article-title>Vitamin D signalling pathways in cancer: potential for anticancer therapeutics.</article-title><source>Nat Rev Cancer</source><volume>7</volume><fpage>684</fpage><lpage>700</lpage><pub-id pub-id-type="pmid">17721433</pub-id></citation></ref><ref id="pone.0005988-Bikle2"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bikle</surname><given-names>DD</given-names></name></person-group><year>2004</year><article-title>Vitamin D and skin cancer.</article-title><source>J Nutr</source><volume>134</volume><fpage>3472S</fpage><lpage>3478S</lpage><pub-id pub-id-type="pmid">15570056</pub-id></citation></ref><ref id="pone.0005988-Bouillon1"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bouillon</surname><given-names>R</given-names></name><name><surname>Eelen</surname><given-names>G</given-names></name><name><surname>Verlinden</surname><given-names>L</given-names></name><name><surname>Mathieu</surname><given-names>C</given-names></name><name><surname>Carmeliet</surname><given-names>G</given-names></name><etal/></person-group><year>2006</year><article-title>Vitamin D and cancer.</article-title><source>J Steroid Biochem Mol Biol</source><volume>102</volume><fpage>156</fpage><lpage>162</lpage><pub-id pub-id-type="pmid">17113979</pub-id></citation></ref><ref id="pone.0005988-vandenBemd1"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van den Bemd</surname><given-names>GJ</given-names></name><name><surname>Chang</surname><given-names>GT</given-names></name></person-group><year>2002</year><article-title>Vitamin D and vitamin D analogs in cancer treatment.</article-title><source>Curr Drug Targets</source><volume>3</volume><fpage>85</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">11899952</pub-id></citation></ref><ref id="pone.0005988-Spina1"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Spina</surname><given-names>CS</given-names></name><name><surname>Tangpricha</surname><given-names>V</given-names></name><name><surname>Uskokovic</surname><given-names>M</given-names></name><name><surname>Adorinic</surname><given-names>L</given-names></name><name><surname>Maehr</surname><given-names>H</given-names></name><etal/></person-group><year>2006</year><article-title>Vitamin D and cancer.</article-title><source>Anticancer Res</source><volume>26</volume><fpage>2515</fpage><lpage>2524</lpage><pub-id pub-id-type="pmid">16886659</pub-id></citation></ref><ref id="pone.0005988-Holick3"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Holick</surname><given-names>MF</given-names></name></person-group><year>2007</year><article-title>Vitamin D deficiency.</article-title><source>N Engl J Med</source><volume>357</volume><fpage>266</fpage><lpage>281</lpage><pub-id pub-id-type="pmid">17634462</pub-id></citation></ref><ref id="pone.0005988-Dusso1"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dusso</surname><given-names>AS</given-names></name><name><surname>Brown</surname><given-names>AJ</given-names></name><name><surname>Slatopolsky</surname><given-names>E</given-names></name></person-group><year>2005</year><article-title>Vitamin D.</article-title><source>Am J Physiol Renal Physiol</source><volume>289</volume><fpage>F8</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">15951480</pub-id></citation></ref><ref id="pone.0005988-Nagpal1"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nagpal</surname><given-names>S</given-names></name><name><surname>Na</surname><given-names>S</given-names></name><name><surname>Rathnachalam</surname><given-names>R</given-names></name></person-group><year>2005</year><article-title>Noncalcemic actions of vitamin D receptor ligands.</article-title><source>Endocr Rev</source><volume>26</volume><fpage>662</fpage><lpage>687</lpage><pub-id pub-id-type="pmid">15798098</pub-id></citation></ref><ref id="pone.0005988-Saito1"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saito</surname><given-names>T</given-names></name><name><surname>Okamoto</surname><given-names>R</given-names></name><name><surname>Haritunians</surname><given-names>T</given-names></name><name><surname>O'Kelly</surname><given-names>J</given-names></name><name><surname>Uskokovic</surname><given-names>M</given-names></name><etal/></person-group><year>2008</year><article-title>Novel Gemini vitamin D(3) analogs have potent antitumor activity.</article-title><source>J Steroid Biochem Mol Biol</source></citation></ref><ref id="pone.0005988-Holick4"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Holick</surname><given-names>MF</given-names></name></person-group><year>2003</year><article-title>Evolution and function of vitamin D.</article-title><source>Recent Results Cancer Res</source><volume>164</volume><fpage>3</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">12899511</pub-id></citation></ref><ref id="pone.0005988-Bikle3"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bikle</surname><given-names>DD</given-names></name></person-group><year>2004</year><article-title>Vitamin D regulated keratinocyte differentiation.</article-title><source>J Cell Biochem</source><volume>92</volume><fpage>436</fpage><lpage>444</lpage><pub-id pub-id-type="pmid">15156556</pub-id></citation></ref><ref id="pone.0005988-Wiseman1"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wiseman</surname><given-names>H</given-names></name></person-group><year>1993</year><article-title>Vitamin D is a membrane antioxidant. Ability to inhibit iron-dependent lipid peroxidation in liposomes compared to cholesterol, ergosterol and tamoxifen and relevance to anticancer action.</article-title><source>FEBS Lett</source><volume>326</volume><fpage>285</fpage><lpage>288</lpage><pub-id pub-id-type="pmid">8325381</pub-id></citation></ref><ref id="pone.0005988-Holick5"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Holick</surname><given-names>MF</given-names></name></person-group><year>2003</year><article-title>Vitamin D deficiency: what a pain it is.</article-title><source>Mayo Clin Proc</source><volume>78</volume><fpage>1457</fpage><lpage>1459</lpage><pub-id pub-id-type="pmid">14661673</pub-id></citation></ref><ref id="pone.0005988-Bikle4"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bikle</surname><given-names>DD</given-names></name></person-group><year>2007</year><article-title>What is new in vitamin D: 2006&#x02013;2007.</article-title><source>Curr Opin Rheumatol</source><volume>19</volume><fpage>383</fpage><lpage>388</lpage><pub-id pub-id-type="pmid">17551371</pub-id></citation></ref><ref id="pone.0005988-Bikle5"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bikle</surname><given-names>DD</given-names></name><name><surname>Ng</surname><given-names>D</given-names></name><name><surname>Tu</surname><given-names>CL</given-names></name><name><surname>Oda</surname><given-names>Y</given-names></name><name><surname>Xie</surname><given-names>Z</given-names></name></person-group><year>2001</year><article-title>Calcium- and vitamin D-regulated keratinocyte differentiation.</article-title><source>Mol Cell Endocrinol</source><volume>177</volume><fpage>161</fpage><lpage>171</lpage><pub-id pub-id-type="pmid">11377831</pub-id></citation></ref><ref id="pone.0005988-Holick6"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Holick</surname><given-names>MF</given-names></name></person-group><year>2000</year><article-title>Calcium and vitamin D. Diagnostics and therapeutics.</article-title><source>Clin Lab Med</source><volume>20</volume><fpage>569</fpage><lpage>590</lpage><pub-id pub-id-type="pmid">10986622</pub-id></citation></ref><ref id="pone.0005988-Bikle6"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bikle</surname><given-names>DD</given-names></name><name><surname>Oda</surname><given-names>Y</given-names></name><name><surname>Xie</surname><given-names>Z</given-names></name></person-group><year>2004</year><article-title>Calcium and 1,25(OH)2D: interacting drivers of epidermal differentiation.</article-title><source>J Steroid Biochem Mol Biol</source><volume>89&#x02013;90</volume><fpage>355</fpage><lpage>360</lpage></citation></ref><ref id="pone.0005988-Li1"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Verma</surname><given-names>IM</given-names></name></person-group><year>2002</year><article-title>NF-kappaB regulation in the immune system.</article-title><source>Nat Rev Immunol</source><volume>2</volume><fpage>725</fpage><lpage>734</lpage><pub-id pub-id-type="pmid">12360211</pub-id></citation></ref><ref id="pone.0005988-VanWaes1"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van Waes</surname><given-names>C</given-names></name></person-group><year>2007</year><article-title>Nuclear factor-kappaB in development, prevention, and therapy of cancer.</article-title><source>Clin Cancer Res</source><volume>13</volume><fpage>1076</fpage><lpage>1082</lpage><pub-id pub-id-type="pmid">17317814</pub-id></citation></ref><ref id="pone.0005988-Liu1"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Xia</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>F</given-names></name><name><surname>Park</surname><given-names>E</given-names></name><name><surname>Carbajal</surname><given-names>S</given-names></name><etal/></person-group><year>2008</year><article-title>IKKalpha is required to maintain skin homeostasis and prevent skin cancer.</article-title><source>Cancer Cell</source><volume>14</volume><fpage>212</fpage><lpage>225</lpage><pub-id pub-id-type="pmid">18772111</pub-id></citation></ref><ref id="pone.0005988-Umezawa1"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Umezawa</surname><given-names>K</given-names></name></person-group><year>2006</year><article-title>Inhibition of tumor growth by NF-kappaB inhibitors.</article-title><source>Cancer Sci</source><volume>97</volume><fpage>990</fpage><lpage>995</lpage><pub-id pub-id-type="pmid">16925581</pub-id></citation></ref><ref id="pone.0005988-Grone1"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grone</surname><given-names>A</given-names></name></person-group><year>2002</year><article-title>Keratinocytes and cytokines.</article-title><source>Vet Immunol Immunopathol</source><volume>88</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">12088639</pub-id></citation></ref><ref id="pone.0005988-Freedberg1"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Freedberg</surname><given-names>IM</given-names></name><name><surname>Tomic-Canic</surname><given-names>M</given-names></name><name><surname>Komine</surname><given-names>M</given-names></name><name><surname>Blumenberg</surname><given-names>M</given-names></name></person-group><year>2001</year><article-title>Keratins and the keratinocyte activation cycle.</article-title><source>J Invest Dermatol</source><volume>116</volume><fpage>633</fpage><lpage>640</lpage><pub-id pub-id-type="pmid">11348449</pub-id></citation></ref><ref id="pone.0005988-Banno1"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Banno</surname><given-names>T</given-names></name><name><surname>Gazel</surname><given-names>A</given-names></name><name><surname>Blumenberg</surname><given-names>M</given-names></name></person-group><year>2004</year><article-title>Effects of tumor necrosis factor-alpha (TNF alpha) in epidermal keratinocytes revealed using global transcriptional profiling.</article-title><source>J Biol Chem</source><volume>279</volume><fpage>32633</fpage><lpage>32642</lpage><pub-id pub-id-type="pmid">15145954</pub-id></citation></ref><ref id="pone.0005988-Banno2"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Banno</surname><given-names>T</given-names></name><name><surname>Gazel</surname><given-names>A</given-names></name><name><surname>Blumenberg</surname><given-names>M</given-names></name></person-group><year>2005</year><article-title>Pathway-specific profiling identifies the NF-kappa B-dependent tumor necrosis factor alpha-regulated genes in epidermal keratinocytes.</article-title><source>J Biol Chem</source><volume>280</volume><fpage>18973</fpage><lpage>18980</lpage><pub-id pub-id-type="pmid">15722350</pub-id></citation></ref><ref id="pone.0005988-Hayden1"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hayden</surname><given-names>MS</given-names></name><name><surname>Ghosh</surname><given-names>S</given-names></name></person-group><year>2008</year><article-title>Shared principles in NF-kappaB signaling.</article-title><source>Cell</source><volume>132</volume><fpage>344</fpage><lpage>362</lpage><pub-id pub-id-type="pmid">18267068</pub-id></citation></ref><ref id="pone.0005988-Du1"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>Z</given-names></name><name><surname>Wei</surname><given-names>L</given-names></name><name><surname>Murti</surname><given-names>A</given-names></name><name><surname>Pfeffer</surname><given-names>SR</given-names></name><name><surname>Fan</surname><given-names>M</given-names></name><etal/></person-group><year>2007</year><article-title>Non-conventional signal transduction by type 1 interferons: the NF-kappaB pathway.</article-title><source>J Cell Biochem</source><volume>102</volume><fpage>1087</fpage><lpage>1094</lpage><pub-id pub-id-type="pmid">17910035</pub-id></citation></ref><ref id="pone.0005988-Wei1"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>L</given-names></name><name><surname>Sandbulte</surname><given-names>MR</given-names></name><name><surname>Thomas</surname><given-names>PG</given-names></name><name><surname>Webby</surname><given-names>RJ</given-names></name><name><surname>Homayouni</surname><given-names>R</given-names></name><etal/></person-group><year>2006</year><article-title>NFkappaB negatively regulates interferon-induced gene expression and anti-influenza activity.</article-title><source>J Biol Chem</source><volume>281</volume><fpage>11678</fpage><lpage>11684</lpage><pub-id pub-id-type="pmid">16517601</pub-id></citation></ref><ref id="pone.0005988-Yang1"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>CH</given-names></name><name><surname>Murti</surname><given-names>A</given-names></name><name><surname>Pfeffer</surname><given-names>LM</given-names></name></person-group><year>2005</year><article-title>Interferon induces NF-kappa B-inducing kinase/tumor necrosis factor receptor-associated factor-dependent NF-kappa B activation to promote cell survival.</article-title><source>J Biol Chem</source><volume>280</volume><fpage>31530</fpage><lpage>31536</lpage><pub-id pub-id-type="pmid">16009713</pub-id></citation></ref><ref id="pone.0005988-Pfeffer1"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pfeffer</surname><given-names>LM</given-names></name><name><surname>Dinarello</surname><given-names>CA</given-names></name><name><surname>Herberman</surname><given-names>RB</given-names></name><name><surname>Williams</surname><given-names>BR</given-names></name><name><surname>Borden</surname><given-names>EC</given-names></name><etal/></person-group><year>1998</year><article-title>Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons.</article-title><source>Cancer Res</source><volume>58</volume><fpage>2489</fpage><lpage>2499</lpage><pub-id pub-id-type="pmid">9635566</pub-id></citation></ref><ref id="pone.0005988-Pomerantz1"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pomerantz</surname><given-names>JL</given-names></name><name><surname>Baltimore</surname><given-names>D</given-names></name></person-group><year>2002</year><article-title>Two pathways to NF-kappaB.</article-title><source>Mol Cell</source><volume>10</volume><fpage>693</fpage><lpage>695</lpage><pub-id pub-id-type="pmid">12419209</pub-id></citation></ref><ref id="pone.0005988-Schon1"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schon</surname><given-names>MP</given-names></name><name><surname>Boehncke</surname><given-names>WH</given-names></name></person-group><year>2005</year><article-title>Psoriasis.</article-title><source>N Engl J Med</source><volume>352</volume><fpage>1899</fpage><lpage>1912</lpage><pub-id pub-id-type="pmid">15872205</pub-id></citation></ref><ref id="pone.0005988-Nagpal2"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nagpal</surname><given-names>S</given-names></name></person-group><year>2003</year><article-title>An orphan meets family members in skin.</article-title><source>J Invest Dermatol</source><volume>120</volume><fpage>viii</fpage><lpage>x</lpage><pub-id pub-id-type="pmid">12542546</pub-id></citation></ref><ref id="pone.0005988-Masuda1"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Masuda</surname><given-names>S</given-names></name><name><surname>Jones</surname><given-names>G</given-names></name></person-group><year>2006</year><article-title>Promise of vitamin D analogues in the treatment of hyperproliferative conditions.</article-title><source>Mol Cancer Ther</source><volume>5</volume><fpage>797</fpage><lpage>808</lpage><pub-id pub-id-type="pmid">16648549</pub-id></citation></ref><ref id="pone.0005988-Bikle7"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bikle</surname><given-names>D</given-names></name><name><surname>Teichert</surname><given-names>A</given-names></name><name><surname>Hawker</surname><given-names>N</given-names></name><name><surname>Xie</surname><given-names>Z</given-names></name><name><surname>Oda</surname><given-names>Y</given-names></name></person-group><year>2007</year><article-title>Sequential regulation of keratinocyte differentiation by 1,25(OH)2D3, VDR, and its coregulators.</article-title><source>J Steroid Biochem Mol Biol</source><volume>103</volume><fpage>396</fpage><lpage>404</lpage><pub-id pub-id-type="pmid">17229570</pub-id></citation></ref><ref id="pone.0005988-Oda1"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oda</surname><given-names>Y</given-names></name><name><surname>Ishikawa</surname><given-names>MH</given-names></name><name><surname>Hawker</surname><given-names>NP</given-names></name><name><surname>Yun</surname><given-names>QC</given-names></name><name><surname>Bikle</surname><given-names>DD</given-names></name></person-group><year>2007</year><article-title>Differential role of two VDR coactivators, DRIP205 and SRC-3, in keratinocyte proliferation and differentiation.</article-title><source>J Steroid Biochem Mol Biol</source><volume>103</volume><fpage>776</fpage><lpage>780</lpage><pub-id pub-id-type="pmid">17223341</pub-id></citation></ref><ref id="pone.0005988-Hawker1"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hawker</surname><given-names>NP</given-names></name><name><surname>Pennypacker</surname><given-names>SD</given-names></name><name><surname>Chang</surname><given-names>SM</given-names></name><name><surname>Bikle</surname><given-names>DD</given-names></name></person-group><year>2007</year><article-title>Regulation of human epidermal keratinocyte differentiation by the vitamin D receptor and its coactivators DRIP205, SRC2, and SRC3.</article-title><source>J Invest Dermatol</source><volume>127</volume><fpage>874</fpage><lpage>880</lpage><pub-id pub-id-type="pmid">17082781</pub-id></citation></ref><ref id="pone.0005988-Zella1"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zella</surname><given-names>LA</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Shevde</surname><given-names>NK</given-names></name><name><surname>Pike</surname><given-names>JW</given-names></name></person-group><year>2006</year><article-title>Enhancers located within two introns of the vitamin D receptor gene mediate transcriptional autoregulation by 1,25-dihydroxyvitamin D3.</article-title><source>Mol Endocrinol</source><volume>20</volume><fpage>1231</fpage><lpage>1247</lpage><pub-id pub-id-type="pmid">16497728</pub-id></citation></ref><ref id="pone.0005988-Lippens1"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lippens</surname><given-names>S</given-names></name><name><surname>Denecker</surname><given-names>G</given-names></name><name><surname>Ovaere</surname><given-names>P</given-names></name><name><surname>Vandenabeele</surname><given-names>P</given-names></name><name><surname>Declercq</surname><given-names>W</given-names></name></person-group><year>2005</year><article-title>Death penalty for keratinocytes: apoptosis versus cornification.</article-title><source>Cell Death Differ</source><volume>12</volume><issue>Suppl 2</issue><fpage>1497</fpage><lpage>1508</lpage><pub-id pub-id-type="pmid">16247497</pub-id></citation></ref><ref id="pone.0005988-Riis1"><label>55</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Riis</surname><given-names>JL</given-names></name><name><surname>Johansen</surname><given-names>C</given-names></name><name><surname>Gesser</surname><given-names>B</given-names></name><name><surname>Moller</surname><given-names>K</given-names></name><name><surname>Larsen</surname><given-names>CG</given-names></name><etal/></person-group><year>2004</year><article-title>1alpha,25(OH)(2)D(3) regulates NF-kappaB DNA binding activity in cultured normal human keratinocytes through an increase in IkappaBalpha expression.</article-title><source>Arch Dermatol Res</source><volume>296</volume><fpage>195</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">15372276</pub-id></citation></ref><ref id="pone.0005988-CohenLahav1"><label>56</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cohen-Lahav</surname><given-names>M</given-names></name><name><surname>Douvdevani</surname><given-names>A</given-names></name><name><surname>Chaimovitz</surname><given-names>C</given-names></name><name><surname>Shany</surname><given-names>S</given-names></name></person-group><year>2007</year><article-title>The anti-inflammatory activity of 1,25-dihydroxyvitamin D3 in macrophages.</article-title><source>J Steroid Biochem Mol Biol</source><volume>103</volume><fpage>558</fpage><lpage>562</lpage><pub-id pub-id-type="pmid">17267205</pub-id></citation></ref><ref id="pone.0005988-CohenLahav2"><label>57</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cohen-Lahav</surname><given-names>M</given-names></name><name><surname>Shany</surname><given-names>S</given-names></name><name><surname>Tobvin</surname><given-names>D</given-names></name><name><surname>Chaimovitz</surname><given-names>C</given-names></name><name><surname>Douvdevani</surname><given-names>A</given-names></name></person-group><year>2006</year><article-title>Vitamin D decreases NFkappaB activity by increasing IkappaBalpha levels.</article-title><source>Nephrol Dial Transplant</source><volume>21</volume><fpage>889</fpage><lpage>897</lpage><pub-id pub-id-type="pmid">16455676</pub-id></citation></ref><ref id="pone.0005988-Sun1"><label>58</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Kong</surname><given-names>J</given-names></name><name><surname>Duan</surname><given-names>Y</given-names></name><name><surname>Szeto</surname><given-names>FL</given-names></name><name><surname>Liao</surname><given-names>A</given-names></name><etal/></person-group><year>2006</year><article-title>Increased NF-kappaB activity in fibroblasts lacking the vitamin D receptor.</article-title><source>Am J Physiol Endocrinol Metab</source><volume>291</volume><fpage>E315</fpage><lpage>322</lpage><pub-id pub-id-type="pmid">16507601</pub-id></citation></ref><ref id="pone.0005988-Ren1"><label>59</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>Q</given-names></name><name><surname>Kari</surname><given-names>C</given-names></name><name><surname>Quadros</surname><given-names>MR</given-names></name><name><surname>Burd</surname><given-names>R</given-names></name><name><surname>McCue</surname><given-names>P</given-names></name><etal/></person-group><year>2006</year><article-title>Malignant transformation of immortalized HaCaT keratinocytes through deregulated nuclear factor kappaB signaling.</article-title><source>Cancer Res</source><volume>66</volume><fpage>5209</fpage><lpage>5215</lpage><pub-id pub-id-type="pmid">16707445</pub-id></citation></ref><ref id="pone.0005988-Bar1"><label>60</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bar</surname><given-names>M</given-names></name><name><surname>Domaschke</surname><given-names>D</given-names></name><name><surname>Meye</surname><given-names>A</given-names></name><name><surname>Lehmann</surname><given-names>B</given-names></name><name><surname>Meurer</surname><given-names>M</given-names></name></person-group><year>2007</year><article-title>Wavelength-dependent induction of CYP24A1-mRNA after UVB-triggered calcitriol synthesis in cultured human keratinocytes.</article-title><source>J Invest Dermatol</source><volume>127</volume><fpage>206</fpage><lpage>213</lpage><pub-id pub-id-type="pmid">16902422</pub-id></citation></ref><ref id="pone.0005988-Slominski5"><label>61</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Slominski</surname><given-names>AT</given-names></name><name><surname>Zmijewski</surname><given-names>MA</given-names></name><name><surname>Semak</surname><given-names>I</given-names></name><name><surname>Sweatman</surname><given-names>T</given-names></name><name><surname>Janjetovic</surname><given-names>Z</given-names></name><etal/></person-group><year>2009</year><article-title>Sequential metabolism of 7-dehydrocholesterol to steroidal 5,7-dienes in adrenal glands and its biological implication in the skin.</article-title><source>PLoS ONE</source><volume>4</volume><fpage>e4309</fpage><pub-id pub-id-type="pmid">19190754</pub-id></citation></ref><ref id="pone.0005988-Zmijewski1"><label>62</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zmijewski</surname><given-names>MA</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Zjawiony</surname><given-names>JK</given-names></name><name><surname>Sweatman</surname><given-names>TW</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><etal/></person-group><year>2008</year><article-title>Synthesis and photo-conversion of androsta- and pregna-5,7-dienes to vitamin D3-like derivatives.</article-title><source>Photochem Photobiol Sci</source><volume>7</volume><fpage>1570</fpage><lpage>1576</lpage><pub-id pub-id-type="pmid">19037511</pub-id></citation></ref><ref id="pone.0005988-Zbytek2"><label>63</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zbytek</surname><given-names>B</given-names></name><name><surname>Pfeffer</surname><given-names>LM</given-names></name><name><surname>Slominski</surname><given-names>AT</given-names></name></person-group><year>2003</year><article-title>Corticotropin-releasing hormone inhibits nuclear factor-kappaB pathway in human HaCaT keratinocytes.</article-title><source>J Invest Dermatol</source><volume>121</volume><fpage>1496</fpage><lpage>1499</lpage><pub-id pub-id-type="pmid">14675201</pub-id></citation></ref><ref id="pone.0005988-Karin1"><label>64</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Karin</surname><given-names>M</given-names></name><name><surname>Yamamoto</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>QM</given-names></name></person-group><year>2004</year><article-title>The IKK NF-kappa B system: a treasure trove for drug development.</article-title><source>Nat Rev Drug Discov</source><volume>3</volume><fpage>17</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">14708018</pub-id></citation></ref><ref id="pone.0005988-Li2"><label>65</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Carpio</surname><given-names>DF</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Bruzzo</surname><given-names>P</given-names></name><name><surname>Singh</surname><given-names>V</given-names></name><etal/></person-group><year>2001</year><article-title>An essential role of the NF-kappa B/Toll-like receptor pathway in induction of inflammatory and tissue-repair gene expression by necrotic cells.</article-title><source>J Immunol</source><volume>166</volume><fpage>7128</fpage><lpage>7135</lpage><pub-id pub-id-type="pmid">11390458</pub-id></citation></ref><ref id="pone.0005988-Zbytek3"><label>66</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zbytek</surname><given-names>B</given-names></name><name><surname>Pfeffer</surname><given-names>LM</given-names></name><name><surname>Slominski</surname><given-names>AT</given-names></name></person-group><year>2004</year><article-title>Corticotropin-releasing hormone stimulates NF-kappaB in human epidermal keratinocytes.</article-title><source>J Endocrinol</source><volume>181</volume><fpage>R1</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">15171702</pub-id></citation></ref><ref id="pone.0005988-Reichrath1"><label>67</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reichrath</surname><given-names>J</given-names></name><name><surname>Rappl</surname><given-names>G</given-names></name></person-group><year>2003</year><article-title>Ultraviolet light (UV)-induced immunosuppression: is vitamin D the missing link?</article-title><source>J Cell Biochem</source><volume>89</volume><fpage>6</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">12682903</pub-id></citation></ref><ref id="pone.0005988-Lehmann3"><label>68</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lehmann</surname><given-names>B</given-names></name></person-group><year>1997</year><article-title>HaCaT cell line as a model system for vitamin D3 metabolism in human skin.</article-title><source>J Invest Dermatol</source><volume>108</volume><fpage>78</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">8980292</pub-id></citation></ref><ref id="pone.0005988-Gurlek1"><label>69</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gurlek</surname><given-names>A</given-names></name><name><surname>Pittelkow</surname><given-names>MR</given-names></name><name><surname>Kumar</surname><given-names>R</given-names></name></person-group><year>2002</year><article-title>Modulation of growth factor/cytokine synthesis and signaling by 1alpha,25-dihydroxyvitamin D(3): implications in cell growth and differentiation.</article-title><source>Endocr Rev</source><volume>23</volume><fpage>763</fpage><lpage>786</lpage><pub-id pub-id-type="pmid">12466189</pub-id></citation></ref><ref id="pone.0005988-Pisarchik1"><label>70</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pisarchik</surname><given-names>A</given-names></name><name><surname>Slominski</surname><given-names>A</given-names></name></person-group><year>2004</year><article-title>Molecular and functional characterization of novel CRFR1 isoforms from the skin.</article-title><source>Eur J Biochem</source><volume>271</volume><fpage>2821</fpage><lpage>2830</lpage><pub-id pub-id-type="pmid">15206947</pub-id></citation></ref><ref id="pone.0005988-Hanissian1"><label>71</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hanissian</surname><given-names>SH</given-names></name><name><surname>Akbar</surname><given-names>U</given-names></name><name><surname>Teng</surname><given-names>B</given-names></name><name><surname>Janjetovic</surname><given-names>Z</given-names></name><name><surname>Hoffmann</surname><given-names>A</given-names></name><etal/></person-group><year>2004</year><article-title>cDNA cloning and characterization of a novel gene encoding the MLF1-interacting protein MLF1IP.</article-title><source>Oncogene</source><volume>23</volume><fpage>3700</fpage><lpage>3707</lpage><pub-id pub-id-type="pmid">15116101</pub-id></citation></ref><ref id="pone.0005988-Hanissian2"><label>72</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hanissian</surname><given-names>SH</given-names></name><name><surname>Teng</surname><given-names>B</given-names></name><name><surname>Akbar</surname><given-names>U</given-names></name><name><surname>Janjetovic</surname><given-names>Z</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><etal/></person-group><year>2005</year><article-title>Regulation of myeloid leukemia factor-1 interacting protein (MLF1IP) expression in glioblastoma.</article-title><source>Brain Res</source><volume>1047</volume><fpage>56</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">15893739</pub-id></citation></ref><ref id="pone.0005988-Zbytek4"><label>73</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zbytek</surname><given-names>B</given-names></name><name><surname>Pfeffer</surname><given-names>LM</given-names></name><name><surname>Slominski</surname><given-names>AT</given-names></name></person-group><year>2006</year><article-title>CRH inhibits NF-kappa B signaling in human melanocytes.</article-title><source>Peptides</source><volume>27</volume><fpage>3276</fpage><lpage>3283</lpage><pub-id pub-id-type="pmid">16959375</pub-id></citation></ref><ref id="pone.0005988-Pavicevic1"><label>74</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pavicevic</surname><given-names>Z</given-names></name><name><surname>Leslie</surname><given-names>CC</given-names></name><name><surname>Malik</surname><given-names>KU</given-names></name></person-group><year>2008</year><article-title>cPLA2 phosphorylation at serine-515 and serine-505 is required for arachidonic acid release in vascular smooth muscle cells.</article-title><source>J Lipid Res</source><volume>49</volume><fpage>724</fpage><lpage>737</lpage><pub-id pub-id-type="pmid">18187403</pub-id></citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>This work was supported by NIH grant R01AR052190. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group></back></article> 